Ivabradine JensonR



This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Ivabradine JensonR (ivabradine) has been withdrawn at the request of the marketing authorisation holder

This EPAR was last updated on 20/12/2018

Authorisation details

Product details
Ivabradine JensonR
Agency product number
Active substance
ivabradine hydrochloride
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Angina Pectoris
  • Heart Failure
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
JensonR+ Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Fishleigh Court
Fishleigh Road
Barnstaple EX31 3UD
United Kingdom

Product information

11/11/2016 Ivabradine JensonR - EMEA/H/C/004217 - -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Cardiac therapy

Therapeutic indication

Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

Assessment history

How useful was this page?

Add your rating